Preclinical studies have shown promising results with IGF-1R inhibitors in SCLC [131, 132]; however, a phase II clinical trial has failed to prove efficacy of the IGF-1R inhibitor linsitinib (OSI-906) in unselected SCLC patients [119]. Here, IGF1R is linked to small cell lung carcinoma.